07/03/20 KDx Diagnostics Announces CE Marking for Innovative Non-invasive URO17™ Bladder Cancer Test

July 26, 20200

KDx Diagnostics, Inc., announced today that it has received Conformité Européene (CE) Marking for its innovative and proprietary urine-based test (the URO17™ test) for bladder cancer … Read More

Leave a Reply

Your email address will not be published. Required fields are marked *